Monitoring clinical and microbiological evolution of a cystic fibrosis patient over 26 years: experience of a Brazilian CF Centre
Tóm tắt
Burkholderia cepacia complex is a group of opportunistic pathogens in cystic fibrosis (CF) patients believed to be associated with poor prognosis and patient-to-patient transmissibility. Little is known about clinical outcomes after B. vietnamiensis chronic colonization/infection. A 33 yo male patient had diagnosis of CF by 7 yo, after recurrent pneumonia during infancy and lobectomy (left upper lobe) at 6 yo. Burkholderia cepacia complex (Bcc) was first isolated by 13 yo, and the patient fulfilled the criteria for chronic colonization by 15 yo. In the following 16 years (1997–2013), there was intermittent isolation of P. aeruginosa and continuous isolation of Bcc, identified as B. vietnamiensis. There was clinical and laboratorial stability for 16 years with annual rate of decline in forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) of 1.61 and 1.35%, respectively. From 2013 to 2015, there was significant clinical and lung function deterioration: annual rate of decline in FEV1 and FVC was 3 and 4.1%, respectively while body mass index decreased from 18.1 to 17.1. Episodes of hemoptysis and respiratory exacerbations (with hospital admissions) became more frequent. CF related diabetes was diagnosed (fasting glycemia: 116 mg/dL, oral glucose tolerance test: 305 mg/dL). Because of the severity of the disease in the last years, in addition to traditional microbiological surveillance, microbiome analysis by next generation sequencing (NGS) was performed on respiratory secretions. The NGS showed that 97% of the sequencing data were attributed to genus Burkholderia.
We report the case of a 33-year-old male CF patient known to have chronic infection with B. vietnamiensis who remained clinically stable for 16 years and presented recent clinical and laboratorial deterioration. Microbiome analysis of respiratory secretions was performed in 3 samples collected in 2014–2015. Clinical deterioration overlapped with cystic fibrosis-related diabetes and microbiome composition revealed no significant differences when compared microbiome results to culture dependent methods.
Tài liệu tham khảo
Smet BD, Mayo M, Peeters C, Zlosnik JEA, Spilker T, Hird TJ, LiPuma JL, Kidd TJ, Kaestli M, Ginther JL, Wagner DM, Keim P, Bell SC, Jacobs JA, Currie BJ, Vandamme P. Burkholderia stagnalis sp. nov. and Burkholderia territorii sp. nov., two novel Burkholderia cepacia complex species from environmental and human sources. Int J Syst Bacteriol. 2015;65:2265–71.
Vicenzi FJ, Pillonetto M, Souza HAPHM, Palmeiro JK, Riedi CA, Rosario-Filho NA, Dalla-Costa LM. Polyphasic characterisation of Burkholderia cepacia complex species isolated from children with cystic fibrosis. Mem Inst Oswaldo Cruz. 2016;111(1):37–42.
Courtney JM, Dunbar KEA, Mc Dowel A, Moore JE, Warke TJ, Stevenson M, Elborn JS. Clinical outcome of Burkholderia cepacia complex in cystic fibrosis adults. J Cyst Fibros. 2004;3:93–8.
Jones AM, Dodd ME, Govan JRW, Barcus V, Doherty CJ, Morris J, Webb AK. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax. 2004;59:948–51.
Kalish LA, Waltz DA, Dovey M, Potter-Bynoe G, McAdam AJ, LiPuma JJ, Gerard C, Goldmann D. Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am J Respir Crit Care Med. 2006;173(4):421–5.
Folescu TW, Costa CH, Cohen RWF, Neto OCC, Albano RM, Marques EA. Burkholderia cepacia complex: clinical course in cystic fibrosis patients. BMC Pulm Med. 2015;15:158–63.
Carvalho GM, Carvallho AP, Folescu TX, Higa L, Teixeira LM, Plotkowski MC, Merquior VL, Albano RM, Marques EA. Transient isolation of Burkholderia multivorans and Burkholderia cenocepacia from a Brazilian cystic fibrosis patient chronically colonized with Burkholderia vietnamiensis. J Cyst Fibros. 2005;4(4):267–70.
Judge EP, Dodd JD, Masterson JB, Gakkagher CG. Pulmonary abnormalities on high-resolution CT demonstrate more rapid decline than FEV1 in adults with cystic fibrosis. Chest. 2006;130(5):1424–32.
Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Huntley J, Fierer N, Owens SM, Betley J, Fraser L, Bauer M, Gromley N, Gilbert JA, Smith G, Knight R. Ultra- high-throughput microbial community analysis on the Illumina HiSeq amd MiSeq platforms. ISME J. 2012;6(8):1621–4.
McCloskey M, McCaughan J, Redmond A, Elborn JS. Clinical outcome after acquisition of Burkholderia cepacia in patients with cystic fibrosis. Ir J Med Sci. 2001;170(1):28–31.
Correia S, Nascimento C, Pereira L, Cunha MV, Sá-Correia I, Barreto C. The clinical course of Burkholderia cepacia complex bacteria respiratory infection in cystic fibrosis patients. Rev Port Pneumol. 2008;14(1):5–26.
Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, Stokes DC, Wohl ME, Wagener JS, Regelmann WE, Johnson CA. Scientific advisory group and the investigators and coordinators of the epidemiologic study of cystic fibrosis. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr. 2007;151(2):34–9.
Moran A, Becker D, Casella SJ, Gottlieb PA, Kirkman MS, Marshall BC, Slovis B. Epidemiology, pathophysiology, and prognostic implications if cystic fibrosis-related diabetes. Diabetes Care. 2010;33(12):2677–83.
Alves CAD, Aguiar RA, Alves ACS, Santana MA. Diabetes mellitus in patients with cystic fibrosis. J Bras Pneumol. 2007;33(2):213–21.